Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VNDA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVanda Pharmaceuticals General Counsel Timothy Williams resigns effective April 10
Filed April 2, 2026 · Period ending March 29, 2026 · ~1 min read
Key Changes
-
medium
Timothy Williams resigned as Senior Vice President, General Counsel and Secretary effective April 10, 2026, citing pursuit of other endeavors. No successor has been named.
Item 5.02 verify on EDGAR →
Summary
Vanda Pharmaceuticals disclosed that Timothy Williams, its top legal officer, will step down on April 10, 2026. Williams served as Senior Vice President, General Counsel and Secretary, overseeing legal affairs and corporate governance. The company stated he is leaving to pursue other opportunities, with no indication of disagreement or conflict.
No replacement has been announced yet. For retail investors, executive departures at the General Counsel level typically have limited immediate impact on operations or financial performance, but the position is critical for regulatory compliance and legal risk management. Watch for the company's announcement of a successor and whether any legal or compliance issues emerge during the transition period.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify